<?xml version="1.0" encoding="UTF-8"?>
<ref id="B6">
 <label>6</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Reck</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Rodriguez-Abreu</surname>
    <given-names>D</given-names>
   </name>
   <name>
    <surname>Robinson</surname>
    <given-names>AG</given-names>
   </name>
   <name>
    <surname>Hui</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Csoszi</surname>
    <given-names>T</given-names>
   </name>
   <name>
    <surname>Fulop</surname>
    <given-names>A</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Pd-L1 Tumor Proportion Score of 50% or Greater</article-title>. 
  <source>J Clin Oncol</source> (
  <year>2019</year>) 
  <volume>37</volume>(
  <issue>7</issue>):
  <page-range>537â€“46</page-range>. 
  <pub-id pub-id-type="doi">10.1200/JCO.18.00149</pub-id>
 </mixed-citation>
</ref>
